1,459 Shares in Allergan plc (NYSE:AGN) Bought by Intrust Bank NA

Intrust Bank NA purchased a new stake in Allergan plc (NYSE:AGN) during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 1,459 shares of the company’s stock, valued at approximately $214,000.

A number of other large investors also recently made changes to their positions in the business. Liberty Wealth Management LLC grew its holdings in shares of Allergan by 108.8% during the first quarter. Liberty Wealth Management LLC now owns 190 shares of the company’s stock worth $27,000 after purchasing an additional 99 shares during the last quarter. Legacy Bridge LLC bought a new stake in shares of Allergan during the first quarter worth $27,000. Patriot Financial Group Insurance Agency LLC grew its holdings in shares of Allergan by 2,162.5% during the first quarter. Patriot Financial Group Insurance Agency LLC now owns 181 shares of the company’s stock worth $27,000 after purchasing an additional 173 shares during the last quarter. Investors Research Corp bought a new stake in shares of Allergan during the first quarter worth $29,000. Finally, JNBA Financial Advisors bought a new stake in shares of Allergan during the fourth quarter worth $30,000. Hedge funds and other institutional investors own 80.15% of the company’s stock.

Shares of NYSE:AGN traded up $15,712,400,233.99 during mid-day trading on Friday, reaching $15,712,400,400.00. 7,228,989 shares of the stock were exchanged, compared to its average volume of 3,152,785. The company has a current ratio of 0.71, a quick ratio of 0.60 and a debt-to-equity ratio of 0.32. The company has a market capitalization of $55.01 billion, a P/E ratio of 941,426,027.56, a P/E/G ratio of 1.52 and a beta of 1.39. Allergan plc has a one year low of $114.27 and a one year high of $197.00. The business’s 50 day moving average price is $132.85.

Allergan (NYSE:AGN) last posted its quarterly earnings data on Tuesday, May 7th. The company reported $3.79 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.55 by $0.24. The business had revenue of $3.60 billion during the quarter, compared to the consensus estimate of $3.55 billion. Allergan had a positive return on equity of 8.45% and a negative net margin of 45.94%. Allergan’s quarterly revenue was down 2.0% on a year-over-year basis. During the same period last year, the company earned $3.74 earnings per share. As a group, research analysts forecast that Allergan plc will post 16.68 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Friday, June 14th. Investors of record on Tuesday, May 14th were issued a dividend of $0.74 per share. The ex-dividend date was Monday, May 13th. This represents a $2.96 dividend on an annualized basis and a dividend yield of 0.00%. Allergan’s payout ratio is presently 17.74%.

Several equities analysts have recently issued reports on AGN shares. Raymond James lowered Allergan from an “outperform” rating to a “market perform” rating in a research note on Tuesday. Bank of America set a $197.00 target price on Allergan and gave the company a “buy” rating in a research note on Thursday, March 7th. Jefferies Financial Group initiated coverage on Allergan in a research note on Monday, April 15th. They issued a “hold” rating and a $144.95 target price on the stock. SunTrust Banks initiated coverage on Allergan in a research note on Tuesday, March 19th. They issued a “buy” rating and a $178.00 target price on the stock. Finally, Royal Bank of Canada set a $165.00 target price on Allergan and gave the company a “hold” rating in a research note on Monday, March 25th. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating and nine have given a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $176.90.

Allergan Profile

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products.

Recommended Story: How interest rates affect municipal bond prices

Institutional Ownership by Quarter for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.